Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.
Schmiegelow K, Attarbaschi A, Barzilai S, Escherich G, Frandsen TL, Halsey C, Hough R, Jeha S, Kato M, Liang DC, Mikkelsen TS, Möricke A, Niinimäki R, Piette C, Putti MC, Raetz E, Silverman LB, Skinner R, Tuckuviene R, van der Sluis I, Zapotocka E; Ponte di Legno toxicity working group. Schmiegelow K, et al. Among authors: moricke a. Lancet Oncol. 2016 Jun;17(6):e231-e239. doi: 10.1016/S1470-2045(16)30035-3. Lancet Oncol. 2016. PMID: 27299279 Free article. Review.
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL.
Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, Parasole R, Linderkamp C, Flotho C, Petit A, Micalizzi C, Zeng Y, Desai R, Kormany WN, Eckert C, Möricke A, Sartor M, Hrusak O, Peters C, Saha V, Vinti L, von Stackelberg A. Locatelli F, et al. Among authors: moricke a. Leukemia. 2023 Jan;37(1):222-225. doi: 10.1038/s41375-022-01770-3. Epub 2022 Dec 8. Leukemia. 2023. PMID: 36482128 Free PMC article. No abstract available.
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, Löning L, Beier R, Ludwig WD, Ratei R, Harbott J, Boos J, Mann G, Niggli F, Feldges A, Henze G, Welte K, Beck JD, Klingebiel T, Niemeyer C, Zintl F, Bode U, Urban C, Wehinger H, Niethammer D, Riehm H, Schrappe M; German-Austrian-Swiss ALL-BFM Study Group. Möricke A, et al. Blood. 2008 May 1;111(9):4477-89. doi: 10.1182/blood-2007-09-112920. Epub 2008 Feb 19. Blood. 2008. PMID: 18285545 Free article. Clinical Trial.
Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA. Attarbaschi A, et al. Among authors: moricke a. J Clin Oncol. 2008 Jun 20;26(18):3046-50. doi: 10.1200/JCO.2008.16.1117. J Clin Oncol. 2008. PMID: 18565891
Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.
van der Linden MH, Valsecchi MG, De Lorenzo P, Möricke A, Janka G, Leblanc TM, Felice M, Biondi A, Campbell M, Hann I, Rubnitz JE, Stary J, Szczepanski T, Vora A, Ferster A, Hovi L, Silverman LB, Pieters R. van der Linden MH, et al. Among authors: moricke a. Blood. 2009 Oct 29;114(18):3764-8. doi: 10.1182/blood-2009-02-204214. Epub 2009 Aug 5. Blood. 2009. PMID: 19657114 Free article. Clinical Trial.
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, Klingebiel T, Zintl F, Niemeyer C, Kremens B, Niggli F, Niethammer D, Welte K, Stanulla M, Odenwald E, Riehm H, Schrappe M. Möricke A, et al. Leukemia. 2010 Feb;24(2):265-84. doi: 10.1038/leu.2009.257. Epub 2009 Dec 10. Leukemia. 2010. PMID: 20010625 Clinical Trial.
Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
Pichler H, Möricke A, Mann G, Teigler-Schlegel A, Niggli F, Nebral K, König M, Inthal A, Krehan D, Dworzak MN, Janousek D, Harbott J, Schrappe M, Gadner H, Strehl S, Haas OA, Panzer-Grümayer R, Attarbaschi A; Berlin-Frankfurt-Münster (BFM) Study Group. Pichler H, et al. Among authors: moricke a. Br J Haematol. 2010 Apr;149(1):93-100. doi: 10.1111/j.1365-2141.2009.08059.x. Epub 2010 Jan 13. Br J Haematol. 2010. PMID: 20067563 Free article. Clinical Trial.
Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey.
Bienemann K, Burkhardt B, Modlich S, Meyer U, Möricke A, Bienemann K, Mauz-Körholz C, Escherich G, Zimmermann M, Körholz D, Janka-Schaub G, Schrappe M, Reiter A, Borkhardt A. Bienemann K, et al. Among authors: moricke a. Br J Haematol. 2011 Nov;155(4):468-76. doi: 10.1111/j.1365-2141.2011.08863.x. Epub 2011 Sep 19. Br J Haematol. 2011. PMID: 21923652 Free article.
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Lauten M, Möricke A, Beier R, Zimmermann M, Stanulla M, Meissner B, Odenwald E, Attarbaschi A, Niemeyer C, Niggli F, Riehm H, Schrappe M. Lauten M, et al. Among authors: moricke a. Haematologica. 2012 Jul;97(7):1048-56. doi: 10.3324/haematol.2011.047613. Epub 2012 Jan 22. Haematologica. 2012. PMID: 22271901 Free PMC article. Clinical Trial.
109 results